×
搜尋
About
About SHINER
History
Research
News
Certificate/License
Events
Product
Drug Products
Medical Devices
Oral Supplements
Cooperate
Consulation Services
In-Licensing/Out-Licensing
Drug Products
Medical Devices
Oral Supplements
Contact
CH /
EN
About shinerpharm
Company Profile
Corporate Vision
Research and Development
Business Cooperation
Latest News
Latest News
Product Introduction
Drug Products
Medical Devices
Oral Supplements
Recruitment
104 Job Bank
Staff Center
News
HOME
News
Certificate / License
Certificate / License
Events
Certificate / License
Shiner's Phenbuty 500mg Tablets receives TFDA approval. (NDA, the orphan drug, API: sodium phenylbutyrate)
07
2015-12
Certificate / License
Shiner's pms-Methylphenidate ER 36mg Tablets receives TFDA approval for the treatment of ADHD. (ANDA, API: methylphenidate hydrochloride)
20
2015-07
Certificate / License
Shiner receives approval and plans to establish a formulation plant in Hsinchu Science Park Zhunan Campus.
01
2015-04
Certificate / License
L-Carnit "Shiner" Injection 1g/5ml receives TFDA approval. (NDA, the orphan drug, API: levocarnitine)
04
2015-03
Certificate / License
Shiner's Shilifil 100mg F.C. Tablets receives TFDA approval for the treatment of erectile dysfunction. (ANDA, API: sildenafil citrate)
20
2014-10
Certificate / License
Shiner's "GelX" Oral Gel (Non-sterile) receives TFDA approval. (Medical Device, Liquid bandage)
25
2014-04
Certificate / License
Shiner's Haxasin XL Tablets 4mg receives TFDA approval for the treatment of the symptoms of an enlarged prostate, benign prostatic hyperplasia or BPH.
10
2013-05
Certificate / License
Shiner's Pantopro Gastro-Resistant Tablets 40mg receives TFDA approval; combining two appropriate antimicrobial agents.
27
2012-12
Certificate / License
Shiner's Reosteo 35mg Tablets receives TFDA approval. (ANDA, API: risedronate sodium)
25
2012-10
Certificate / License
The collection of Hanlosin S.R.O.D. Tablets 0.2 mg. (ANDA, API: Tamsulosin hydrochloride)
22
2011-04
←
1
2
→